A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.

Plain-language guide to PMID 25667132 (2015): multicenter observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 70 patients.

Key Facts

PMID: 25667132
Journal: Advances in therapy
Year: 2015
Study type: Observational Study
Authors: Borrás Pérez V et al. (14 authors)
DOI: 10.1007/s12325-015-0181-9

What This Study Did, in Plain Language

What Was Tested

This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The aim of this study was to determine the adult height achieved by the Spanish children who participated in the initial Phase III clinical trial, and to evaluate the long-term safety of rhGH treatment.

Why It Was Studied

At the end of the study, those patients still growing were offered to remain on treatment (as in usual clinical practice), and continued to be monitored.

Who Took Part

According to the abstract, 70 patients were involved.

PubMed indexes the participants as children and teenagers, both men and women.

This study was a multicenter, observational, retrospective follow-up study of patients who participated in the Phase III clinical trial (70 patients recruited).

Auxological parameters [including height, height velocity, and their associated height standard deviation scores (HSDS)] were obtained from 39 patients.

How the Study Was Run

The researchers set it up as a multicenter study.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

Safety was assessed by recording any adverse events (AEs).

What Was Measured

Topics PubMed links to this paper include Body Height, Growth Disorders and Human Growth Hormone.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 70 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Advances in therapy), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.